SUBSCRIBE
SUBSCRIBE
News   Drug Development

Regeneron Pharmaceuticals, Inc., Bayer HealthCare Say Eye Drug Meets Mid-stage Goal

February 18, 2010 | 
1 min read
Bookmark and Share

Reuters -- Regeneron Pharmaceuticals and Bayer HealthCare, a U.S. unit of Germany's Bayer, said their experimental drug to treat retinal swelling brought on by diabetes, met its primary goal in a mid-stage study.
Clinical research Phase 2 Phase 3
Regeneron Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
 · 
1 min read
 · 
Heather McKenzie
A close-up of a zebra standing in the Okavango Delta, showcasing its distinctive black and white stripes. The background is a blur of natural vegetation.
Insights
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
February 4, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Mechanical weight scale, body mass control concept : Bathroom scale on pale blue wood background. Analog scale operated with spring that pressure is calibrated to translate tension into a mass readout.
Obesity
Pfizer’s First Weight-Loss Data After Metsera Buy ‘Look Competitive’
February 3, 2026
 · 
2 min read
 · 
Tristan Manalac
Life is full of challenges and unexpected obstacles. Use these experiences as motivation to keep pushing forward and striving for your goals
Antibody-drug conjugate (ADC)
Daiichi Sankyo Dumps Next-Gen ADC From Development Pipeline
February 3, 2026
 · 
2 min read
 · 
Tristan Manalac